Fibroblast growth factor receptor 2 is associated with poor overall survival in clear cell carcinoma of the ovary and may be a novel therapeutic approach

2014 Fiscal Year Final Research Report

• Project/Area Number: 24592517
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Obstetrics and gynecology
• Research Institution: Tottori University
• Principal Investigator: ITAMOCHI Hiroaki 鳥取大学, 医学部, 准教授 (20314601)
• Co-Investigator(Kenkyū-buntansha): SATO Syinya 鳥取大学, 医学部附属病院, 助教 (10423261) ; SATO Seiya 鳥取大学, 医学部附属病院, 助教 (30621007) ; HARADA Tasuku 鳥取大学, 医学部, 教授 (40218649) ; SHIMADA Muneaki 鳥取大学, 医学部, 講師 (40362892) ; CHIKUMI Jun 鳥取大学, 医学部附属病院, 医員 (70467702) ; OISHI Tetsuro 鳥取大学, 医学部附属病院, 講師 (80359877) ; KIGAWA Junzo 鳥取大学, 医学部附属病院, 教授 (00177784)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: 卵巣明細胞腺癌 / FGFR2

Outline of Final Research Achievements

We previously found that gene and protein expression of FGFR2 were increased in ovarian clear cell carcinoma (CCC); here, we examined FGFR2 expression in CCC tumor tissues and its correlation with clinical parameters. We also analyzed the effect of an FGFR inhibitor on the growth of CCC cells to investigate whether FGFR2 could be a therapeutic target for this disease. The expressions of FGFR2 were found in 96%of CCC. The 5-year survival rate for patients with a moderate or strong expression of FGFR2 was significantly lower than that for those with an absent or poor expression of FGFR2 (54% vs 79%). Multivariable analysis revealed that FGFR2 expression was independent prognostic factors. The FGFR inhibitor effectively suppressed the growth of CCC cells with induction of G1 cell cycle arrest and down-regulated the expression of phosphorylated Akt and phosphorylated ERK. We conclude that FGFR2 is an important biomarker predictive of patient outcome and is a potential target for CCC.

Free Research Field

婦人科腫瘍学